Calls
1
Mike Gustar
President and CEO, Novo Nordisk
Win Rate
0.0%
return
-28.3%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 13
$60.50
-28.3%
Gustar says the new oral Wegovy pill expands the GLP-1 market by removing injection phobia, taboo, and refrigeration barriers; it delivers the same 16.6% weight loss and cardiovascular benefits as the injectable at accessible prices ($149-$249, $25 with insurance), addressing a large untreated obesity population. He also highlights rare disease launches in sickle cell and hemophilia.
GLP-1 / Obesity
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Mike Gustar has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: NVO.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
